NCT06829329View on ClinicalTrials.gov

Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

October 21, 2025

Study Completion Date

November 30, 2025

Conditions
Chronic Hepatitis B
Interventions
DRUG

AHB-137

AHB-137 will be administered .

DRUG

NAs

NAs will be administered.

DRUG

Placebo

Placebo will be administered .

Trial Locations (4)

310052

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

401336

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

Unknown

Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou

The Third People's Hospital of Zhenjiang, Zhenjiang

All Listed Sponsors
lead

Ausper Biopharma Co., Ltd.

INDUSTRY